Importantly, the implicated pathways correspond with our prior observations concerning NUCB2‐related immunoregulatory molecules, suggesting a putative immunomodulatory axis wherein NUCB2 expression by tumour cells contributes to CD8+ T‐cell dysfunction via enhanced interferon signalling and complement activation. The gene discussed is NUCB2; the disease is neoplasm.